Floatz logo

Ont-10

Advanced Breast Carcinoma

Cascadian Therapeutics Inc.Phase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

20 Active assets in the Advanced Breast Carcinoma cohort.

Asset / SponsorPhaseRating
Trastuzumab Deruxtecan
SWOG Cancer Research Network
Phase 4BBB
Vinorelbine
Sun Yat-sen University
Phase 3BB
Atezolizumab
Dana-Farber Cancer Institute
Phase 3BB
Enzalutamide
Nuvation Bio Inc.
Phase 2BB
Niraparib
OHSU Knight Cancer Institute
Phase 3BB

View all 23 →

Same molecule, other indications

Ont-10 is also rated in:

Advanced Ovarian CarcinomaDormant
CC
Indicative ·
46 / 100
View asset →
neoplasmDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →